Research Advances in Endocrine Therapy for Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
10.3971/j.issn.1000-8578.2026.25.0873
- VernacularTitle:激素受体阳性/HER2阴性早期乳腺癌内分泌治疗研究进展
- Author:
Wenqin HUANG
1
;
Yalong YANG
1
;
Xinhong WU
1
;
LAMBERTINI MATTEO
2
;
Hongmei ZHENG
1
Author Information
1. Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty Discipline Construction Program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan 430079, China.
2. Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova 16132, Italy;Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova 16132, Italy.
- Publication Type:SPECIALFEATURE
- Keywords:
Breast neoplasms;
Hormone receptor positive;
HER2;
Endocrine therapy;
Ovarian function suppression;
CDK4/6 inhibitor;
Ovarian protection;
Fertility preservation
- From:
Cancer Research on Prevention and Treatment
2026;53(3):169-175
- CountryChina
- Language:Chinese
-
Abstract:
Hormone receptor (HR)-positive/HER2-negative early breast cancer is the most common subtype of breast cancer, and endocrine therapy serves as the cornerstone of adjuvant treatment. In recent years, with the publication of key clinical trials such as SOFT, TEXT, and monarchE, and breakthroughs in novel agents studies like lidERA, the endocrine therapy strategy for HR-positive/HER2-negative early breast cancer has evolved toward increased precision and intensity. This article systematically reviews the latest advances in endocrine therapy, focusing on the consolidation of ovarian function suppression as a standard for high-risk premenopausal patients with updated follow-up evidence, the benefit-risk assessment of extended endocrine therapy, and the current application and interdrug differences of CDK4/6 inhibitors in the adjuvant setting. This manuscript also addresses existing challenges, including optimizing treatment-related quality of life and precisely identifying beneficiary populations, and briefly introduces the clinical trial progress of novel agents, such as oral selective estrogen receptor degraders. Furthermore, it outlines evidence-based strategies for ovarian protection during chemotherapy and fertility preservation for young patients. This review aims to provide clinicians with a comprehensive perspective, balancing the pursuit of maximal efficacy with patients′ long-term quality of life and individualized needs.
